Effects of antileukotriene among asthmatic patients.
OBJECTIVE
To determine the effect of antileukotriene (montelukast) 10 mg once daily for the treatment of mild to moderate asthma.


METHODS
Open label, prospective.


METHODS
Thirty asthmatic patients > or = 18 years of age with baseline FEV1 > 60 per cent and < or = 80 per cent of predicted values and evidence of reversible airway obstruction, as defined by an increase in FEV1 of > or = 20 per cent.


METHODS
Montelukast 10 mg once daily orally for 12 weeks, back up beta-2 agonist inhaler was available.


RESULTS
Spirometry was performed during the screening period, and every month after starting antileukotriene. Subjects recorded asthma-related symptoms and use of supplement beta-2 agonists daily on diary cards. Over 12 weeks of treatment, the FEV1 increased 10 per cent, 14 per cent and 19 per cent respectively, compared to the baseline (p < 0.05). The physician and patients evaluation scores were quite good in the study.


CONCLUSIONS
Oral montelukast once daily gave a favorable effect in management of mild to moderate asthmatic patients.
Saenghirunvattana
S
S
Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
D000085:Acetates / Q000008:administration & dosage / Q000627:therapeutic use*; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D003521:Cyclopropanes; D006801:Humans; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D008875:Middle Aged; D011446:Prospective Studies; D011804:Quinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D013147:Spirometry; D013440:Sulfides; D016896:Treatment Outcome
D000085:Acetates; D018927:Anti-Asthmatic Agents; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; C093875:montelukast